We're bringing back a fan favorite — Lily Zargami, editor and co-founder of Jennie, whose first appearance on Another Bloody Podcast (our most-downloaded episode ever) chronicled a brutal reaction to injectable Mounjaro. Since then, the GLP-1 landscape has changed fast: an oral Wegovy pill hit the market with record-breaking uptake, Eli Lilly's own oral option is racing toward approval, and both drugs are being studied for benefits that go well beyond weight loss — heart failure, artery disease, liver disease, and more.

Lily joins us to talk about what's different this time around on the oral version, how she's learned to manage reflux and eat more intentionally, and the complicated, often unspoken feelings that come with going back on a drug after it once landed you in urgent care. We dig into disordered-eating red flags, the real cost differences between injectables and pills, the "Wild West" of compounded versions, and why neither of us feels guilty anymore about needing long-term medication — for this or anything else.

Content note: this episode includes candid discussion of disordered eating patterns, body image, and weight — listener discretion advised.

Show notes:

You can read Lili Zarghami's essay series, "A Month of Mounjaro" at Jenny Magazine, https://jennymag.com/2024/01/14/mounjaro-diary-part-1/

FDA Approves Novo Nordisk's Wegovy® Pill, the First and Only Oral GLP-1 for Weight Loss in Adults Novo Nordisk (PR Newswire) https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html

First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. CNBC https://www.cnbc.com/2026/01/05/first-glp-1-pill-for-obesity-from-novo-nordisk-launches-in-the-us.html

Novo's Wegovy pill hits over 18,000 US prescriptions in strong debut week Reuters https://www.marketscreener.com/news/novo-s-wegovy-pill-hits-over-18-000-us-prescriptions-in-strong-debut-week-ce7e5bdada88f023

Wegovy® Pill Prescriptions Surpass 3 Million Novo Nordisk (PR Newswire) https://www.prnewswire.com/news-releases/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html

FDA Approves Lilly's Foundayo™ (orforglipron), the Only GLP-1 Pill for Weight Loss That Can Be Taken Any Time of Day Eli Lilly and Company https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill

Wegovy Global Regulatory Status: FDA Approval, EMA Authorization, and Worldwide Access in 2026 HealthRX https://healthrx.com/regulatory-wegovy/global-regulatory

Novo Nordisk's CagriSema Demonstrated Significant Reduction in HbA1c and Weight Across REIMAGINE Program (ADA 2026) Novo Nordisk (PR Newswire) https://www.prnewswire.com/news-releases/novo-nordisks-cagrisema-2-4-mg--2-4-mg-demonstrated-significant-reduction-in-hba1c-and-weight-across-multiple-studies-in-the-reimagine-program-presented-at-ada-2026--302793443.html

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine https://www.nejm.org/doi/full/10.1056/NEJMoa2502081

If this episode brought up anything difficult around food or body image: the National Alliance for Eating Disorders helpline is available at 1-866-662-1235.